Wnt5a: Its Function, Signaling, and Role in Disease

Wnt5a is a signaling protein that acts as a master coordinator of cell behavior, guiding everything from how an embryo takes shape to how the immune system mounts an inflammatory response. Unlike many members of the broader Wnt protein family, Wnt5a works primarily through so-called non-canonical pathways, meaning it generally does not operate through the well-known beta-catenin route that most Wnt proteins favor. That distinction matters because it gives Wnt5a a unique and sometimes contradictory personality in disease: it can suppress tumors in one tissue while fueling their spread in another, calm inflammation in one context while stoking it in the next.

How Wnt5a Talks to Cells

Most Wnt proteins are famous for switching on the canonical pathway, which stabilizes a protein called beta-catenin inside the cell and ultimately changes which genes get turned on. Wnt5a mostly skips that route. Instead, it triggers at least two alternative signaling cascades. One is the planar cell polarity pathway, which controls how cells orient themselves within a tissue and how they move in coordinated groups. The other is the Wnt/calcium pathway, where Wnt5a binding at the cell surface leads to a spike in intracellular calcium. That calcium surge activates downstream enzymes, including calcium/calmodulin-dependent kinase II and protein kinase C, which go on to reshape the cell’s behavior.¹

To receive Wnt5a’s signal, cells use a variety of surface receptors. The Frizzled family of receptors (particularly Frizzled-5 and Frizzled-7) are prominent partners. But Wnt5a also binds receptor tyrosine kinases like ROR2 and Ryk, each of which channels the signal into different cellular responses. Structural studies have shown that the ROR2 receptor’s cysteine-rich domain is essential for relaying Wnt5a signals; when that domain is deleted, cells completely fail to respond.² The Ryk receptor uses a different binding region called the WIF domain to grab Wnt5a, and this interaction is especially important in the developing brain.³ Which receptor a cell expresses largely determines what Wnt5a does to that cell, and this receptor context is one of the main reasons Wnt5a can have such wildly different effects in different tissues.

Wnt5a Can Also Shut Down the Canonical Pathway

Although Wnt5a works through its own non-canonical routes, it also reaches back and interferes with the canonical beta-catenin pathway. One mechanism involves promoting the destruction of beta-catenin through a route that does not require the enzyme GSK-3, which is the usual executioner of beta-catenin. Instead, Wnt5a enlists a different set of proteins, including one called Siah2, to tag beta-catenin for degradation.⁴

But this antagonism is not a universal rule. When purified Wnt5a protein was tested alongside another Wnt family member called Wnt3a, it suppressed canonical signaling in a dose-dependent manner, but the mechanism depended on which receptors were available. In cells carrying the ROR2 receptor, Wnt5a blocked canonical signaling without actually reducing beta-catenin levels; it instead silenced the gene-expression changes that beta-catenin normally drives.⁵ In other receptor contexts, purified Wnt5a can actually activate canonical signaling. The takeaway is that Wnt5a is not simply a canonical inhibitor; what it does depends heavily on which receptors the target cell happens to display.

Shaping the Embryo

During embryonic development, Wnt5a helps orchestrate the elongation of the body axis, a fundamental step in building a properly proportioned animal. In mice, Wnt5a works alongside a close relative called Wnt11 to drive convergent extension, a process in which cells intercalate and rearrange to lengthen tissues along the head-to-tail axis. When both genes are knocked out simultaneously, the notochord (the rod-like structure that runs along the embryo’s midline) fails to extend properly, and cells of the notochord lose their ability to migrate in a coordinated direction.⁶ In experiments tracking individual cells with fluorescent dye, notochord precursor cells in these double-knockout embryos wandered randomly instead of streaming forward along the midline.⁷

Wnt5a is also required for normal limb development. It directs the orientation of cell movements and cell division within the growing limb bud through the JNK signaling branch, helping ensure that the limb grows out in the right direction and at the right proportions.⁸ Mice lacking Wnt5a are born with shortened, malformed limbs and truncated body axes, underscoring how essential this protein is for basic body geometry.

Guiding Nerve Fibers in the Brain

Wnt5a plays a surprisingly specific role in wiring the brain. The corpus callosum, the thick bundle of nerve fibers that connects the left and right hemispheres, relies on Wnt5a to steer axons after they cross the midline. In this setting, Wnt5a acts as a repulsive cue: it pushes callosal axons away from the midline and toward the opposite hemisphere, operating through the Ryk receptor. When Ryk is deleted, cortical axons lose their sensitivity to Wnt5a and grow freely into areas they would normally avoid.³

A separate role exists in the midbrain, where Wnt5a influences dopamine-producing neurons. At early stages of mouse development, Wnt5a promotes the outgrowth of dopaminergic axons. But at later stages, as those axons approach their target in the striatum, Wnt5a switches to repelling them, helping fine-tune where they terminate. Mice lacking Wnt5a show disorganized dopamine neuron fiber bundles and reduced nerve fiber density in the striatum.⁹ This dual behavior, attracting at one developmental stage and repelling at another, fits the broader theme of Wnt5a being deeply context-dependent.

Immune Activation and Inflammation

Wnt5a is not just a developmental signal. It is actively produced by immune cells, particularly macrophages, where it helps sustain inflammatory responses. Macrophage-derived Wnt5a stimulates the release of pro-inflammatory cytokines and also promotes the growth of new blood vessels and lymphatic vessels.¹⁰ In the context of sepsis, researchers demonstrated that a functional Wnt5a/Frizzled-5/CaMKII signaling chain is essential for macrophage inflammatory activation. Blocking this pathway with a soluble receptor fragment called sFRP1 damped down the inflammatory response, suggesting that Wnt5a is a viable target for anti-inflammatory therapy.¹¹

The relationship holds in infectious disease as well. In tuberculosis, Wnt5a helps macrophages mount a vigorous cytokine response. When Wnt5a is absent, the production of key inflammatory molecules such as TNF-alpha, IL-1-beta, IL-12, and IL-6 drops sharply in both lung tissue and bone-marrow-derived macrophages in response to the tuberculosis bacterium.¹² Wnt5a is therefore a double-edged sword in immunity: it strengthens the body’s early defense against pathogens, but if left unchecked, the same inflammatory drive contributes to chronic tissue damage.

Cancer and the Paradox of Wnt5a

Perhaps the most striking feature of Wnt5a in disease is that it can act as both a tumor promoter and a tumor suppressor, depending on the cancer type and the molecular environment. In prostate cancer, Wnt5a promotes tumor progression by driving epithelial-to-mesenchymal transition, a process in which cancer cells become more mobile and invasive, and by interacting with androgen receptor signaling. Yet in prostate cancer cells that have already metastasized to bone, the very same protein can induce dormancy through the ROR2/Siah2 axis, actually putting the brakes on the canonical Wnt/beta-catenin pathway that fuels growth.¹³

In melanoma, Wnt signaling pathways drive a phenomenon called phenotype switching, where tumor cells toggle between a highly proliferative state and a highly invasive state. Wnt5a-driven non-canonical signaling is implicated in pushing melanoma cells toward the invasive phenotype, and all three Wnt signaling branches, canonical, planar cell polarity, and calcium, play roles in melanoma progression and therapy resistance.¹⁴ In tongue squamous cell carcinoma, Wnt5a-ROR2 signaling drives aggressiveness by promoting epithelial-to-mesenchymal transition and the production of enzymes that degrade surrounding tissue.¹⁵

This dual personality creates a real challenge for drug development. You cannot simply block Wnt5a everywhere and expect good outcomes, because in some cancers it is the thing keeping metastasis in check, while in others it is the thing driving invasion forward.

Obesity, Insulin Resistance, and Vascular Disease

Wnt5a has emerged as a significant player in the metabolic complications of obesity. In obese individuals, Wnt5a levels are significantly higher in visceral fat (the fat packed around internal organs) compared to subcutaneous fat. In mouse studies, deleting Wnt5a improved insulin resistance and reduced fat tissue inflammation, while overexpressing Wnt5a specifically in immune cells worsened both problems, all without changing how much fat the animals carried. The mechanism runs through JNK signaling: Wnt5a prompts macrophages in fat tissue to produce inflammatory cytokines, especially IL-6, which in turn impair insulin signaling in nearby fat cells.¹⁶

The damage extends to blood vessels. In arterioles within visceral fat of obese patients, increased WNT5A-JNK signaling correlates with impaired insulin-mediated vasodilation. When researchers blocked JNK pharmacologically, insulin-driven blood vessel relaxation improved roughly sixfold. And when endothelial cells were directly exposed to Wnt5a in the lab, they developed insulin resistance with impaired activation of the enzyme that produces nitric oxide, a key signal for keeping blood vessels flexible.¹⁷ Wnt5a has also been implicated in atherosclerosis, where it promotes the abnormal growth and migration of smooth muscle cells in blood vessel walls, a process that contributes to plaque formation.¹⁸

Tissue Scarring and Fibrosis

When tissue repair goes wrong and scarring spirals out of control, Wnt5a is often part of the problem. Researchers identified Wnt5a as a dominant non-canonical Wnt ligand in several fibrotic diseases, including systemic sclerosis (scleroderma), sclerodermatous chronic graft-versus-host disease, and idiopathic pulmonary fibrosis. In these conditions, Wnt5a stimulates fibroblasts to transform into myofibroblasts, the contractile, collagen-producing cells that stiffen and scar tissues. The mechanism involves Wnt5a activating latent TGF-beta, one of the most powerful pro-fibrotic signals in the body.¹⁹ Because TGF-beta itself is already a major drug target in fibrosis research, the discovery that Wnt5a acts upstream of it, essentially flipping the switch that unleashes TGF-beta, opens up a potentially earlier point of intervention.

Stem Cell Renewal After Injury and Aging

Wnt5a is also important for the recovery of blood-forming stem cells after injury. Inside bone marrow, specialized stromal cells secrete Wnt5a in response to radiation damage, and this signal helps hematopoietic stem cells regenerate. The pathway works by suppressing a transcription factor called Prox1 in stem cells, keeping them in a state that favors self-renewal rather than premature differentiation. In aged mice, this system falters: Prox1 levels climb inappropriately in irradiated stem cells, and stem cell recovery suffers. But treating aged mice with Wnt5a improved their blood cell repopulation after radiation.²⁰ These findings suggest Wnt5a could eventually be exploited to boost bone marrow recovery in patients undergoing radiation therapy or suffering from age-related decline in blood cell production.

Therapeutic Strategies Targeting Wnt5a

Given Wnt5a’s involvement in cancer metastasis, inflammation, fibrosis, and metabolic disease, researchers have been developing tools to either mimic or block its activity. Two small peptides have attracted the most attention. Foxy-5 is a six-amino-acid peptide that mimics Wnt5a’s action. In a mouse model of breast cancer, injections of Foxy-5 reduced the metastatic spread of tumor cells from the mammary gland to the lungs and liver by roughly 70 to 90 percent, without affecting the primary tumor’s growth rate or triggering cell death.²¹ The idea behind Foxy-5 is that in cancers where Wnt5a is lost and that loss is what unleashes metastasis, restoring the signal with a small peptide could keep tumor cells in place.

Box5 takes the opposite approach. This modified hexapeptide blocks Wnt5a signaling and was designed for cancers where Wnt5a is the problem, not the solution. In melanoma cells that express high levels of Wnt5a, Box5 inhibited migration and invasion by directly interfering with Wnt5a-induced protein kinase C and calcium signaling.²² Structural biology has contributed to this effort as well: antibodies targeting the ROR2 receptor’s cysteine-rich domain have shown potent activation of Wnt5a-dependent signaling at very low concentrations, raising the possibility of using engineered antibodies to fine-tune the pathway in either direction.²

The existence of both an agonist (Foxy-5) and an antagonist (Box5) derived from the same parent protein highlights just how context-dependent Wnt5a therapy would need to be. A drug that helps in breast cancer could theoretically worsen melanoma, and vice versa. Any clinical strategy will have to be matched carefully to the specific tumor biology.

An Ancient and Conserved Signal

Wnt5a is not a recent evolutionary invention. When researchers tested Wnt5 proteins from the sea anemone Nematostella vectensis, a cnidarian whose lineage split from vertebrates over 600 million years ago, they found that the anemone’s version could activate the same non-canonical signaling pathways in frog embryos that vertebrate Wnt5a does. The structural features responsible for distinguishing canonical from non-canonical Wnt activity appear to have been established in the common ancestor of cnidarians and vertebrates and have been conserved throughout animal evolution.²³ That deep conservation suggests that non-canonical Wnt signaling, including the cell polarity and tissue movement programs that Wnt5a controls, was solving fundamental problems in multicellular body construction long before vertebrates appeared on the scene.

How Wnt5a Gets Out of the Cell

Before Wnt5a can signal to neighboring cells, it needs to be processed and secreted by the cell that produces it. All Wnt proteins are lipid-modified, meaning they get a fatty acid chain attached before they leave the cell. An enzyme called Porcupine handles this modification, adding a palmitoleate group that is critical for the protein’s ability to bind its receptors. A second protein called Wntless then ferries the lipid-modified Wnt to the cell surface for release. Studies on a related family member, WNT1, showed that Porcupine and Wntless form a physical complex and actually compete for binding to the Wnt protein. Overexpressing Porcupine enhances lipid modification and helps Wntless shuttle the protein to the surface and out of the cell, but paradoxically, it can reduce the secreted protein’s signaling potency in target cells.²⁴ This secretion machinery is itself a drug target: Porcupine inhibitors are in clinical trials for certain cancers precisely because blocking this step shuts down Wnt secretion across the board.

The involvement of Wnt5a in lung vascular biology adds another clinical dimension. In pulmonary arterial hypertension, cells called pericytes that normally wrap around and stabilize small blood vessels have reduced activity in the planar cell polarity pathway. Restoring the expression of key pathway components, including Frizzled-7 and the small GTPase Cdc42, in these diseased pericytes improved their ability to associate with endothelial cells and form proper vascular networks.²⁵ Although this work focused on downstream components rather than Wnt5a directly, it illustrates how defects anywhere in the non-canonical Wnt signaling chain can contribute to vascular disease, and how restoring those signals holds therapeutic promise.